Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

February 16, 2023

Study Completion Date

February 16, 2023

Conditions
RadiodermatitisDermatitis, Radiation-Induced
Interventions
DEVICE

DermoRelizema cream

Fingertip units (FTU) depending from the extent of the affected skin to treat, two times per day for 7 (±3) days prior RT until about 14 (±3) days post RT end. The product can be used for further 2 weeks (from V3 to V4) in case of need, according to the investigator's judgment

DEVICE

Dexeryl

FTUs depending on the extent of the affected skin to treat, two times per day. The treatment will be applied since 7 (±3) days prior to RT start and will continue until 14 days post RT end (98-112 applications in total).

Trial Locations (1)

41134

Modena University Hospital, Modena

All Listed Sponsors
lead

Relife Italia S.r.l.

INDUSTRY

NCT04483856 - Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis. | Biotech Hunter | Biotech Hunter